Home > Back to Publisher > Report Information

Outlook for the Migraine Market With Novel Approaches Limited, Triptans Dominate

Decision Resources
December 18, 2006
21 Pages - SKU: DECR1399788

Abstract Table of Contents Related Reports

Introduction:

The treatment of migraine is an underserved, underdiagnosed market with great growth potential. Despite the current dominance of triptan therapies, the upcoming entrance of new formulations and new applications of existing treatments, as well as the introduction of new therapeutic agents, will likely substantially alter the market.

Get the Answers You Need to Shape Your Strategy:

No significantly new treatment for migraine has been launched since the advent of the 5-HT1 agonists, also known as triptans. Are there other potentially effective treatments on the horizon?

What effect could new treatments have on the current market?

Two areas of migraine treatment exist: prophylactic, which seeks to prevent the occurrence of migraine, and abortive, which treats the symptoms of migraine after they have begun. What room for growth does each of these treatment areas contain? Which area holds the most growth potential? What are some of the roadblocks to new treatment development?

GlaxoSmithKline's fi rst patent on Imitrex is scheduled to expire in July 2007. What effect will this have on the market? What products are poised to enter the market? What is GSK doing to protect its current market dominance? What can other companies do to take advantage of this imminent patent expiration?

Scope:

Migraine background: Symptoms, triggers, etiology, and possible implicated neurotransmitters.
Patient population: Size and makeup of migraine patient populations worldwide.
Current approaches to migraine treatment: Current migraine treatments; their mechanisms of action; characteristics such as onset of action and duration of action, effi cacy, and side effects; and the factors infl uencing treatment choice.
Current market: Current migraine market, both domestic and international.
Emerging migraine therapies: New formulations of and delivery systems for existing drugs and the development of new agents. Timetable for testing and market entry for each emerging therapy.
Market outlook: The near future for markets in the United States, Europe, and Japan; factors that will affect the market; and possible future scenarios.

Please note, the PDF e-mail from publisher version of this report is for a global site license.

Additional Information

Companies Mentioned in this Spectrum Report:

Abbott
Alexza
Almirall
Applied Pharma Research
Aradigm
Ariston
AstraZeneca
Bayer
Boehringer Ingelheim
Cobalt Pharmaceuticals
Dr. Reddy’s Laboratories
Eisai
Elan
Endo Pharmaceuticals
GlaxoSmithKline
Johnson & Johnson
Kyorin
Menarini
Merck
Minster Pharmaceutical
Mylan
NovaDel
Novartis
Organon
Pierre Fabre
Pfi zer
Pozen
ProEthic
Ranbaxy
Roche
Schwarz Pharma
Spectrum Pharmaceuticals
Torrey Pines Therapeutics
Valeant Pharmaceuticals
Vernalis
Winston
Wyeth
Zogenix

Outlook for the Migraine Market With Novel Approaches Limited, Triptans Dominate

Share this report

Other tasks

Research Assistance

Related Markets

CNS/Neurology Reports

Free Alert Me service